Liraglutide is a novel glucagon-like peptide 1 analogue, which shows promise as a safe, effective therapy for type 2 diabetes. This review discusses the pathophysiology of type 2 diabetes, focusing on the incretin system, and reviews the pharmacology of liraglutide. A concise discussion of preclinical and clinical data is given, highlighting the benefits of liraglutide with respect to glycaemic control, weight modulation and extraglycaemic effects. This article also review some of recent patents related to the field.
Keywords: Liraglutide, type 2 diabetes, incretins, glucagon like peptide-1 (GLP-1)
Rights & PermissionsPrintExport